Absence of evidence that the pro re nata regimen confers benefit: A review of the studies

Kazunari Yoshida, Takefumi Suzuki, Hiroyuki Uchida, Masaru Mimura

研究成果: Review article査読

8 被引用数 (Scopus)

抄録

Studies were sought that evaluated the prevalence, effectiveness, and safety of pro re nata (p.r.n.) medications in psychiatric practice for which evidence has been scarce despite their wide application. To this end, a systematic literature search was performed using various search engines (last search: October 2012) with cross-referencing. A total of 34 studies were identified: 16 studies on epidemiological usage, 16 retrospective studies on effectiveness/safety as well as reasons, and only two prospective studies on the effectiveness/safety of p.r.n. medications. All the patients studied were inpatients, and the reasons for p.r.n. were acute behavioral dyscontrol in 29 studies. Psychiatric diagnoses and outcome measures to assess effectiveness/safety varied and were described in 27 and 20 studies, respectively. Medications under study included antipsychotics (mainly chlorpromazine, haloperidol, olanzapine, risperidone, or quetiapine), benzodiazepines (mainly diazepam and lorazepam), and antihistamines (mainly diphenhydramine). Altogether, 17 studies reported that p.r.n. medications were effective in psychiatric inpatients. Those two prospective studies targeted solely a child/adolescent population with small sample sizes. Currently available data are limited in number, quality, and scope; there has been only equivocal evidence to guide the choice of p.r.n. medications for psychiatric patients, hence there is a need for more investigations on this important clinical topic.

本文言語English
ページ(範囲)228-237
ページ数10
ジャーナルInternational clinical psychopharmacology
28
5
DOI
出版ステータスPublished - 2013 9

ASJC Scopus subject areas

  • 精神医学および精神衛生
  • 薬理学(医学)

フィンガープリント

「Absence of evidence that the pro re nata regimen confers benefit: A review of the studies」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル